Why the study?
Does adriamycin and bleomycin alone or in combination improve tumor response in patients with advanced gynecologic cancers?
Population
56 patients with a variety of advanced stage gynecologic cancers
Comparison
Adriamycin and bleomycin alone and in combination vs Compared against each other
Design
Cohort
Authors
Loading...
May support ADM in advanced uterine sarcomas; leaves open whether BLEO adds benefit in gynecologic cancers.
Does adriamycin and bleomycin alone or in combination improve tumor response in patients with advanced gynecologic cancers?
Adriamycin demonstrates valuable antitumor activity in certain advanced gynecologic cancers, while the addition of bleomycin does not enhance its efficacy.
Barlow et al. (1973) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: